Fatigue Severity Scale

 

Objective[edit | edit source]

The Fatigue Severity Scale is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders. It was originally devised for people with Multiple Sclerosis, systemic lupus erythematosus[1].

[2]

Intended Population[edit | edit source]

Those with a variety of diagnoses including arthritis, fibromyalgia, Multiple sclerosis, Parkinson’s disease and stroke.

Method of Use[edit | edit source]

A self-report scale of nine items about fatigue, its severity and how it affects certain activities. Answers are scored on a seven point scale where 1 = strongly disagree and 7 = strongly agree. This means the minimum score possible is nine and the highest is 63. The higher the score, the more severe the fatigue is and the more it affects the person's activities.

Evidence[edit | edit source]

Reliability[edit | edit source]

Test-retest Reliability[edit | edit source]

Parkinson's Disease:

One study reported excellent test-retest reliability (ICC = 0.91) in a Brazilian-Portuguese version for people with PD (n = 30, mean age = 62 (11) years, mean time post- PD = 7.6 (6.5) years)[3].

Interrater/Intrarater Reliability[edit | edit source]

Not established

Validity[edit | edit source]

Criterion Validity[edit | edit source]

Not established

Construct Validity[edit | edit source]

Convergent Validity[edit | edit source]

Parkinson’s Disease

  • Excellent (r = -0.77) negative correlation with Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale[4]
  • Excellent (r = 0.62) correlation with Nottingham Health Profile (NHP-EN) scale[4]
  • Excellent (r = 0.84) correlation with Parkinson’s Fatigue (PFS) scale (Grace et al, 2006) [5]
  • Poor-adequate (r = 0.22-0.47) correlation with Parkinson’s Disease Questionnaire-39 (PDQ-39) scale (Herlofson et al, 2003; n = 66, mean age = 70.8 (9.9) years, time since PD = 70.2 (56.1) months) [6]

Responsiveness[edit | edit source]

Parkinson’s Disease:

Responsiveness to Pharmocological Intervention Mendoca et al, 2007; n = 17 treatment arm, receiving methyphenidate; mean age = 62.2(10), mean H&Y Stage = 2.58(0.5); n = 19 placebo arm, mean age = 66.3(7.6), mean H&Y Stage = 2.38(0.3) 

  • Those persons in the treatment arm had a significant (p < 0.04) reduction in FSS Score by 6.5 points (from FSS = 43.8 at baseline); Cohen’s d = 0.79
  • Smaller reductions in the placebo group did not reach levels of significance Response to Exercise Intervention: Winward et al, 2010; H&Y 0-4. n = 20 exercise group, mean age = 63.4(6.7); n = 19 control group, mean age = 64.9(9.6)
  • No significant difference in score reduction between exercise and control group at 12 weeks

References[edit | edit source]

  1. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. Arch Neurol. 1989 Oct;46(10):1121-3. The Fatigue Severity Scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-3. Accessed 27 June 2019.
  2. Mometrix Academy. Fatigue severity scale. Available from: https://www.youtube.com/watch?v=XAwDgczNCO0 )last accessed 3.3.2019)
  3. Valderramas, S., Feres, A. C., et al. "Reliability and validity study of a Brazilian-Portuguese version of the fatigue severity scale in Parkinson's disease patients." Arq Neuropsiquiatr 2012 70(7): 497-500
  4. 4.0 4.1 Hagell, P., Hoglund, A., et al. "Measuring fatigue in Parkinson's disease: a psychometric study of two brief generic fatigue questionnaires." J Pain Symptom Manage 2006 32(5): 420-432
  5. Grace, J., Mendelsohn, A., et al. "A comparison of fatigue measures in Parkinson's disease." Parkinsonism Relat Disord 2007 13(7): 443-445
  6. Herlofson, K. and Larsen, J. P. "The influence of fatigue on health-related quality of life in patients with Parkinson's disease." Acta Neurol Scand 2003 107(1): 1-6